Advertisement

Millennium: The Takeda Oncology Company began a second Phase 3 trial on its drug candidate which is already being tested on blood cancer, this time to treat the most common form of amyloidosis, a group of diseases resulting from abnormal deposits of certain proteins.

Advertisement
Advertisement